Treatment outcomes in patients with stage IV large cell neuroendocrine carcinoma: a nationwide registry study
In real-world half of patients with stage IV LCNEC do not receive systemic treatment. Accurate diagnosing LCNEC is challenging and therefore introduces bias (i.e. other diagnoses as SCLC instead of LCNEC) in real-world cohorts, which in turn has impact on analysis of treatment outcomes. Patients with panel-reviewed LCNEC have a poor prognosis and no statistically significant improvement was observed with chemo-immunotherapy.
Authors
- Ernst‐Jan M. Speel (ORCID: https://orcid.org/0000-0002-3016-2989)
- Jan H. von der Thüsen (ORCID: https://orcid.org/0000-0001-9699-4860)
- Lisa M. Hillen (ORCID: https://orcid.org/0000-0002-8808-4952)
- Anne‐Marie C. Dingemans (ORCID: https://orcid.org/0000-0001-6105-182X)
- Jules L. Derks (ORCID: https://orcid.org/0000-0002-0442-1879)
- Teodora Radonic (ORCID: https://orcid.org/0000-0002-6015-5202)
- Michael A. den Bakker (ORCID: https://orcid.org/0000-0001-8996-3134)
- Frank W J Heijboer (ORCID: https://orcid.org/0009-0009-4108-3969)
- Ronald Damhuis (ORCID: https://orcid.org/0000-0001-7248-7047)
- Francien H. van Nederveen
Institutions
- Maastricht University Medical Centre (NL)
- Erasmus MC (NL)
- Albert Schweitzer Ziekenhuis (NL)
- Maasstad Ziekenhuis (NL)
- Dordrecht Hospital (ZA)
- Netherlands Comprehensive Cancer Organisation (NL)
- Erasmus MC Cancer Institute (NL)
- Amsterdam University of Applied Sciences (NL)
- University of Amsterdam (NL)
- Erasmus University Rotterdam (NL)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-11-08
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108830
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- KWF Kankerbestrijding